ADCC News and Research

RSS

Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2

Researchers in France have conducted a study showing that people who are asymptomatic following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – elicit a polyfunctional antibody response to the virus.

16 Nov 2020

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

Balanced B and T cell response required to control SARS-CoV-2

A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.

21 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

New combination therapy can lead to durable responses in patients with multiple myeloma

An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

17 Dec 2019

New study shows response to HIV vaccine in 6 weeks

A US study on DNA-based and protein HIV vaccines has shown that an antibody and cellular immune response occurs within six weeks.

2 Oct 2019

New study shows response to HIV vaccine in 6 weeks

A new study using DNA-based and protein HIV vaccines in various combinations shows that antibody and cellular immune response occurs within 6 weeks from the date of vaccination, and the combination must be administered together for the most rapid protection. This will enable more large-scale testing of the vaccine for effectiveness. About 40 million people today have HIV infections, and 1.2 million deaths a year are related to this infection.

1 Oct 2019

UC San Diego researchers identify new therapeutic approach to kill cancer cells

Epithelial cancers, such as cancers of the lung and pancreas, use the ανβ3 molecule to gain drug resistance to standard cancer therapies and to become highly metastatic.

22 Aug 2019

Pittcon 2019 in Philadelphia proves successful

Pittcon 2019, the 70th annual conference and exposition for analytical chemistry and applied spectroscopy, saw an increase in attendance over last year’s Orlando event.

From Pittcon 11 Apr 2019

Nine top companies win 2019 Pittcon Today Excellence Awards for innovative products

Pittcon, the world’s leading conference and exposition for laboratory science, is pleased to announce the selection of nine finalists in the annual Pittcon Today Excellence Awards conducted by CE Communications, the official publishers of Pittcon Today and the Pittcon Buzz.

From Pittcon 27 Mar 2019

Study reveals how molecular mechanisms regulate lysosomal exocytosis by phagocytes

Lysosomes are filled with more than 50 different hydrolytic enzymes, which are capable of digesting most cellular components.

23 Dec 2018

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

Dr. Robert Britton firmly believes every molecule is important. This chemist doesn't want any molecule sitting unused on a laboratory shelf or in a fridge.

18 May 2018

Penn study finds evidence of AD neuropathology in post-mortem brains of LBD patients

Patients who had a diagnosis of Parkinson's disease (PD) with dementia (PDD) or dementia with Lewy bodies (DLB) and had higher levels of Alzheimer's disease (AD) pathology in their donated post-mortem brains also had more severe symptoms of these Lewy body diseases (LBD) during their lives, compared to those whose brains had less AD pathology, according to research from the Perelman School of Medicine at the University of Pennsylvania.

6 Jan 2017

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.

29 Aug 2016

Penn's ADCC receives $8.8 million grant to continue research on treatment for AD and related dementias

The University of Pennsylvania's Alzheimer's Disease Core Center has been awarded an estimated $8.8 million over five years from the National Institute on Aging to continue its mission of investigating mechanisms, diagnostics, treatments and strategies for Alzheimer's Disease (AD) and related dementias including Parkinson's disease (PD), Parkinson's disease dementia (PDD), Lewy Body dementia (LBD) and frontotemporal lobar degeneration (FTLD).

3 Aug 2016

ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding technologies, today announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics.

19 May 2016

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV-infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

24 Dec 2015

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex Therapeutics, Inc. today presented positive results from the Company’s randomized, double‐blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII‐positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology in Chicago.

2 Jun 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

Scientists design a promising vaccine for herpes viruses

Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine.

9 Mar 2015

ADCC News and Research

Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Balanced B and T cell response required to control SARS-CoV-2

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

New combination therapy can lead to durable responses in patients with multiple myeloma

New study shows response to HIV vaccine in 6 weeks

New study shows response to HIV vaccine in 6 weeks

UC San Diego researchers identify new therapeutic approach to kill cancer cells

Pittcon 2019 in Philadelphia proves successful

Nine top companies win 2019 Pittcon Today Excellence Awards for innovative products

Study reveals how molecular mechanisms regulate lysosomal exocytosis by phagocytes

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

Penn study finds evidence of AD neuropathology in post-mortem brains of LBD patients

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Penn's ADCC receives $8.8 million grant to continue research on treatment for AD and related dementias

ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Scientists design a promising vaccine for herpes viruses

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News